Schweizerischer Nationalfonds / Fonds national suisse
"Developing antibiotics is not profitable, hence the crucial role of universities."
plus
Actualités sur Medikament
Acousia Announces Completion of Patient Enrollment in Phase 2 PROHEAR Study Evaluating ACOU085 (INN: Bimokalner) for the Prevention of Cisplatin-Induced Ototoxicity
Tübingen, Germany (ots) - Acousia Therapeutics GmbH, a clinical-stage biotechnology company developing treatments for acute and chronic inner ear hearing loss, announced the completion of patient enrollment in its Phase 2 PROHEAR clinical study. ACOU085 (INN: Bimokalner) is a proprietary, first-in-class small ...
plusAsklepios Kliniken GmbH & Co. KGaA
Nominations for the Broermann Medical Innovation Award 2026 now open
Hamburg (ots) - - With a million euros, it is one of the world’s most highly endowed awards for medical research The nomination period for the Broermann Medical Innovation Award 2026 has begun. Endowed with a million euros, this international award is among the most prestigious honors for medical research worldwide. Scientists from around the globe who have made ...
plusGrünenthal PRO is joining SHL Medical’s alliance partnership network to offer final assembly service for Molly® autoinjectors
Aachen (ots) - Grünenthal PRO, the contract development and manufacturing organization (CDMO) division of Grünenthal offering a range of services including final assembly of autoinjectors, is entering into a non-exclusive partnership with SHL Medical, a world-leading solutions provider of advanced drug delivery ...
plusUCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress
Brussels (ots/PRNewswire) - - 26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies - Data include an open-label extension study describing the long-term safety of FINTEPLA®▼ (fenfluramine)[1] and global functioning ...
plusSchweizerischer Nationalfonds / Fonds national suisse
Getting a grip on pointless antibiotics prescriptions
Bern (ots) - Patients often push their doctors to prescribe antibiotics unnecessarily, increasing bacterial resistance. More trust in patients could help here. This is the surprising outcome of a study supported by the SNSF. Five million people die each year from bacterial infections because the pathogens are resistant to anti-biotics. According to the World Health Organisation (WHO), this figure will double by 2050. ...
plus
Schweizerischer Nationalfonds / Fonds national suisse
More and more children are allergic to cashew nuts
Bern (ots) - Nuts account for around a quarter of all food allergies. Recently, cashew nuts have been causing a particularly high number of severe reactions in children. This is probably because of increased consumption. Whether as a savoury snack or disguised in gluten-free flour and vegan milk, cashew nuts, which originally come from Brazil, are very much in demand. They are rich in protein but contain less fat and ...
plusCroma-Pharma GmbH Announces Strategic Milestone as Novaestiq Corp. Joins Waldencast
Leobendorf, Austria (ots/PRNewswire) - Saypha® injectables to launch in the U.S. under the Obagi Medical brand, expanding global reach of Croma's science-driven aesthetic solutions Croma-Pharma GmbH, a global leader in minimally invasive aesthetic medicine, today announced the acquisition of Novaestiq Corp. by Waldencast plc (Nasdaq: WALD). Novaestiq, a joint venture ...
plusSchweizerischer Nationalfonds / Fonds national suisse
Tackling antibiotic resistance by capturing bacteria
Bern (ots) - Rapidly identifying certain bacteria allows antibiotic treatments to be optimised. A team from the University of Zurich, supported by the SNSF, has developed molecules to detect and capture certain species. The discovery of antibiotics revolutionised medicine in the 20th century, saving countless lives. However, the emergence of resistant bacteria has quickly become a new challenge. One key factor in tackling ...
plusIsomorphic Labs appoints Dr. Ben Wolf as Chief Medical Officer and establishes US Presence
London and Boston (ots/PRNewswire) - Precision oncology leader joins world-class team as company enters next phase of translating AI-driven drug discovery into life-changing medicines. Isomorphic Labs, the AI-first drug discovery company, has announced the appointment of Ben B. Wolf, M.D., Ph.D., as Chief Medical Officer. Dr. Wolf will be based in the company's newly ...
plusMedHub-AI and Terumo partner to market AI-based FFR in Japan
Tel Aviv, Israel (ots/PRNewswire) - MedHub-AI, pioneer of AI-based FFR "AutocathFFR" software, today announced a distribution agreement with Terumo Corporation to bring AutocathFFR®, its groundbreaking AI-powered Software as a Medical Device (SaMD), to the Japanese market. This partnership marks a new era in coronary physiology assessment where AI technology delivers superior confidence, reproducibility, and clinical ...
plusInnovative Molecules Completes Enrollment of Phase 1b Clinical Trial of IM-250
Munich (ots/PRNewswire) - Innovative Molecules GmbH Announces Completion of Phase 1b Enrollment for IM-250 in Genital Herpes Clinical Trial Innovative Molecules GmbH today announced the completion of enrollment in the Phase 1b portion of its ongoing Phase 1b/2a clinical trial evaluating IM-250, a next-generation helicase-primase inhibitor targeting herpes simplex virus ...
plus
BIAL Announces Oral Presentation at GBA1 Meeting 2025
Porto, Portugal (ots/PRNewswire) - BIAL, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, today announced that it will give an oral presentation on its potential disease-modifying compound, BIA 28-6156, at the GBA1 Meeting 2025 being held June 5-7, 2025, in Montreal, Canada. The GBA1 Meeting 2025 is hosted by McGill University, focusing on all aspects of GBA1 research, from basic ...
plusGrünenthal announces acquisition of the rights to Cialis® from Lilly in Mexico, Brazil & Colombia
Aachen, Germany (ots) - - Grünenthal announces that it agreed to acquire the commercial rights to Cialis® from Eli Lilly and Company in Mexico, Brazil and Colombia, further strengthening Grünenthal's footprint in Latin America. - As part of the acquisition, Grünenthal will transfer the manufacturing of Cialis® to its production site in Chile. - Since 2017, ...
plusASP Isotopes and Isotopia Announce Supply Agreement for Gadolinium-160 to Accelerate Terbium-161 Production for Advanced Cancer Therapies
Petach Tikva, Israel (ots/PRNewswire) - ASP Isotopes Inc. (NASDAQ: ASPI) and Isotopia Molecular Imaging Ltd. have entered into a strategic agreement to secure the supply of Gadolinium-160 (Gd-160), a critical precursor isotope for producing Terbium-161 (Tb-161), an emerging medical isotope with significant potential ...
plusIsotopia and Cardirad Announce Launch of Isoprotrace® in Sweden and Denmark, Expanding Access to Advanced Prostate Cancer Imaging
Petah Tikva, Israel (ots/PRNewswire) - Isotopia Molecular Imaging, in partnership with Cardirad , proudly announces the launch of Isoprotrace®—an advanced Gallium-68 Gozetotide preparation kit for prostate cancer imaging—in Sweden and Denmark. The introduction of Isoprotrace® into these Nordic markets marks a ...
plusx-cardiac and Hemedic Partner to Bring AI-Based Medical Devices to ICUs Across Scandinavia
Berlin/Copenhagen (ots) - x-cardiac GmbH, a leading provider of AI-based health solutions and a spin-off of the German Heart Center of Charité and Charité - Universitätsmedizin Berlin, announced today a strategic distribution partnership with the Danish company Hemedic ApS to expand the reach of its AI-based medical devices in Scandinavia. Through this partnership, ...
plusAstrasana Group receives Swissmedic license for the cultivation of medical cannabis
Zurich (ots) - The Astrasana Group is pleased to announce that its subsidiary, Astrasana Pharma AG, has been granted the official cultivation license for medical cannabis by Swissmedic. This authorization permits the controlled cultivation of cannabis plants with a THC content above 1% and marks an important milestone in the expansion of the Group's pharmaceutical ...
plus
Maren Thurow starts as new Head Global Communications at Grünenthal
Aachen (ots) - Maren Thurow has today assumed the role of Vice President and Head Global Communications at Grünenthal. She succeeds Florian Dieckmann, who has played a key role in evolving the company’s Communications department since 2021. In her new position, Maren will oversee Grünenthal’s communications operations across all markets and lead the team based at ...
plusNeutroFlow: Leading European Medical Consortium Awarded €2.5 Million Grant from EIC Transition Programme to Advance Predictive Biomarker Development for Immunotherapy Response
Heidelberg, Germany, Milan, Seville, Spain and Binyamina, Israel (ots/PRNewswire) - A European-led consortium comprising Heidelberg University Hospital (UKHD), the European Institute of Oncology (IEO), Virgen Macarena University Hospital, and OncoHost today announced that it has been awarded a €2.5 million grant ...
plusAcousia Therapeutics Reaches 50% Patient Enrollment Milestone in Phase 2 PROHEAR Study
Tübingen, Germany (ots) - Acousia Therapeutics GmbH announced that it has successfully enrolled 50% of patients in its ongoing Phase 2 clinical trial, the PROHEAR Study, evaluating ACOU085 (INN: bimokalner) for the prevention of cisplatin-induced hearing loss in patients with testicular cancer undergoing chemotherapy. Cisplatin is a cornerstone in modern oncology and ...
plusImmunity Pharma Presents New Data Supporting the Efficacy of IPL344 in ALS
Jerusalem (ots/PRNewswire) - - Results from phase 2a trial in ALS patients were published in Muscle and Nerve. - Statistically significant 58% to 64% slower ALSFRS-R progression rate in IPL344-treated patients compared to the matched PRO-ACT records. - NfL was reduced by 27% for patients treated for at least two months. - Unadjusted median survival for participants in ...
plusIsomorphic Labs announces $600 million funding to further develop its next-generation AI drug design engine and advance therapeutic programs into the clinic
London (ots/PRNewswire) - Isomorphic Labs will utilise the funding to further power its AI drug design engine through frontier AI research and development and to scale and progress its drug candidate pipeline. Isomorphic Labs, an AI-first drug design and development company, today announced it has raised $600 ...
plusIsomorphic Labs announces $600 million funding to further develop its next-generation AI drug design engine and advance therapeutic programs into the clinic
London (ots/PRNewswire) - Isomorphic Labs will utilise the funding to further power its AI drug design engine through frontier AI research and development and to scale and progress its drug candidate pipeline. Isomorphic Labs, an AI-first drug design and development company, today announced it has raised $600 ...
plus
Briya Expands Access to European Real-World Data Through Strategic Partnership with Casa Sollievo della Sofferenza
San Giovanni Rotondo, Italy (ots/PRNewswire) - Briya, a leading healthcare data retrieval network, is proud to announce a strategic partnership with Casa Sollievo della Sofferenza, one of Italy's premier hospitals renowned for its advanced medical care and research initiatives. This collaboration marks a significant ...
plusSchweizerischer Nationalfonds / Fonds national suisse
Double knock-out for malaria
plusTOOsonix Partners with MikronMed to Introduce Innovative Dermatological Therapy in the Nordic Region
Copenhagen, Denmark (ots/PRNewswire) - A groundbreaking dermatological alliance will bring innovative dermatological treatment to the 27 million residents of the Nordic Region, offering rapid and efficient treatment for the most common skin cancer and various skin conditions - often completed in under 90 seconds. ...
plusApotex licenses exclusive Canadian rights to Qutenza® from Grünenthal
Aachen, Germany & Toronto, Canada, (ots) - Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, announced today that they have entered into a strategic licensing agreement whereby Apotex will have the exclusive Canadian rights to Qutenza®, a topical, non-systemic, ...
plusX4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor - licenced to Norgine for commercialisation in Europe.
London (ots/PRNewswire) - Following the licensing agreement with X4 Pharmaceuticals, Norgine is pleased to see the announcement from X4 today that their Marketing Authorization Application (MAA) for mavorixafor for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis), a rare ...
plusSchweizerischer Nationalfonds / Fonds national suisse
Music to support babies in neonatal intensive care units
Bern (ots) - Certain melodies promote brain development in premature infants. For several years, a team of scientists funded by the SNSF observed this phenomenon. They now know more precisely which areas of the brain react over time. Premature infants are more likely to suffer from attention and emotional regulation disorders. For over a decade, a team funded by the Swiss National Science Foundation (SNSF) has been ...
plus
12345678910Suivant